Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$28.76 +1.50%

+$0.50 today

Market cap
$1.72B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.47M

Average 1.11M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$372.98M

FY 2025 · Annual

Investing Cash Flow

$377.18M

FY 2025 · Annual

+3.8% YoY

Financing Cash Flow

$8.68M

FY 2025 · Annual

-39.9% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(356.51M)(231.8M)(352.09M)673.73M(412.78M)
Depreciation & Amortization9.24M8.56M6.62M5.65M5.18M
Deferred Income Tax00000
Stock-Based Compensation53.51M49.3M44.77M42.85M52.55M
Change in Working Capital(36.82M)(16.43M)(19.06M)(19.77M)(33.04M)
Accounts Receivables(4.38M)(2.21M)(604K)(1.3M)(6.47M)
Inventory0(8.49M)(10.58M)(8.54M)(5.3M)
Accounts Payables1.86M3.44M(8.73M)6.6M1.75M
Other Working Capital(34.31M)(9.17M)864K(16.53M)(23.02M)
Other Non-Cash Items(76.74M)(119.1M)23.69M(1.09B)15.12M
Operating Cash Flow(407.32M)(309.48M)(296.06M)(389.84M)(372.98M)
Capital Expenditures(5.74M)(4.88M)(999K)(1.69M)(4.32M)
Acquisitions (Net)0132.75M040K0
Purchases of Investments(1.38B)(1.03B)(417.93M)(1.54B)(641.76M)
Sales of Investments829.8M1.15B674.68M818.38M1.03B
Other Investing Activities1.8B0(16.18M)1.09B(10M)
Investing Cash Flow1.25B243.26M239.58M363.44M377.18M
Debt Repayment(578K)(331K)000
Common Stock Issued02.68M5.43M14.44M8.68M
Common Stock Repurchased(802.49M)0000
Dividends Paid00000
Other Financing Activities37.3M0000
Financing Cash Flow(765.77M)2.35M5.43M14.44M8.68M
Effect of Forex Changes00000
Net Change in Cash75.69M(63.87M)(51.05M)(11.96M)12.88M
Free Cash Flow(413.06M)(314.36M)(297.06M)(391.53M)(377.29M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$412.8M
+ D&A$5.2M
+ Stock-Based Comp$52.6M
+ Deferred Tax$0
- Working Capital-$33.0M
+ Other Non-Cash$15.1M
= Operating Cash Flow-$373.0M
- Capex-$4.3M
= Free Cash Flow-$377.3M

Analysis

FY2025 free cash flow is -$377.3M. FCF conversion is 91.4% of net income. Operating cash flow was -$373.0M, with capex of -$4.3M. The largest bridge item is Stock-Based Comp at $52.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 13, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
4Statement of changes in beneficial ownershipOct 28, 2026
4Statement of changes in beneficial ownershipOct 23, 2026

Does AGIO generate free cash flow?

Agios Pharmaceuticals, Inc. (AGIO) generated -$377.29M of free cash flow in fiscal 2025.

How much operating cash flow does AGIO produce?

Operating cash flow was -$372.98M, before capital expenditures of $4.32M.